Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, Inc., filed a Form 4 on August 26, 2026, disclosing the sale of 50,160 shares of common stock across three transactions on August 24 and August 25, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Three sales executed: 13,160 shares sold on August 24, 2026, and 20,799 plus 16,201 shares sold on August 25, 2026, for a combined total of 50,160 shares disposed of.
  • Weighted average prices: The three transactions carried weighted average prices of $49.9983, $50.3111, and $51.0576, respectively.
  • Price ranges disclosed: Individual transaction prices ranged from $49.90 to $50.25, $49.90 to $50.88, and $50.91 to $51.39 across the three sales.
  • Remaining ownership: Following the reported transactions, Yeleswaram beneficially owned 195,862 shares of common stock directly.
  • Rule 10b5-1 plan: All three sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
  • Issuer and exchange: The issuer is Rapport Therapeutics, Inc., traded as NASDAQ:RAPP.

Rapport Therapeutics CDO Discloses Multi-Day Share Sales Under Pre-Planned Trading Program

According to the Form 4 filing, Krishnaswamy Yeleswaram, serving as Chief Development Officer of Rapport Therapeutics, Inc. (NASDAQ:RAPP), disposed of common stock over two consecutive trading days. On August 24, 2026, the filing discloses the sale of 13,160 shares at a weighted average price of $49.9983, with individual sale prices ranging from $49.90 to $50.25 inclusive. That transaction reduced direct beneficial ownership from an implied prior position to 232,862 shares.

On August 25, 2026, the filing reports two additional sales. The first involved 20,799 shares at a weighted average price of $50.3111, with prices ranging from $49.90 to $50.88 inclusive, leaving beneficial ownership at 212,063 shares. The second sale on the same date covered 16,201 shares at a weighted average price of $51.0576, with prices ranging from $50.91 to $51.39 inclusive, bringing direct beneficial ownership to 195,862 shares following all reported transactions.

The filing notes that all three transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025. The filing further states that Yeleswaram "undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price." The Form 4 was signed by Troy Ignelzi as Attorney-in-Fact on August 26, 2026.

What Was Disclosed

Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram reported the sale of 50,160 shares of common stock on August 24 and 25, 2026, at weighted average prices between $49.9983 and $51.0576, reducing direct beneficial ownership to 195,862 shares under a pre-established 10b5-1 plan.